Physician profile
Behnaz Rouhani
NPI 1205157484
$3,524.61
in general payments reported to CMS, 2019-2025
16 companies · $2,408 in 2025
The $2,408 reported for 2025 was more than what 90% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $24.05 · 2020: $53.45 · 2021: $133 · 2022: $178 · 2023: $307 · 2024: $422 · 2025: $2,408.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,609 · Food and Beverage: $1,527.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,608.93 |
| Food and Beverage | $1,527.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $2,059.31 | 2024-2025 | |
| Alcon Vision LLC | $343.18 | 2023-2025 | Rocklatan, Tryptyr, Lensx |
| Ocular Therapeutix, INC. | $201.02 | 2020-2025 | Dextenza |
| Allergan, INC. | $165.85 | 2019-2022 | |
| Harrow Eye, LLC | $165.39 | 2025 | Vevye |
| Bausch & Lomb Americas INC. | $142.11 | 2024-2025 | Xiidra, Miebo, Envista Envy Iol |
| Novartis Pharmaceuticals Corporation | $125.97 | 2021-2023 | |
| Oyster Point Pharma, INC. | $57.59 | 2023-2024 | Tyrvaya |
| Carl Zeiss Meditec, INC. | $53.35 | 2020-2023 | |
| Tarsus Pharmaceuticals, INC. | $49.92 | 2024-2025 | Xdemvy |
| Rxsight INC | $42.94 | 2022 | |
| Astellas Pharma US INC | $34.71 | 2025 | Izervay |
| Abbvie INC. | $24.94 | 2022 | |
| Dompe US, INC. | $21.70 | 2025 | Oxervate |
| Aerie Pharmaceuticals, INC. | $19.09 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Thea Pharma INC. | $17.54 | 2025 | Iyuzeh |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Behnaz Rouhani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.